$OCGN Cashflow Statement | Understand Stock

$OCGN

$0.76 +$0.05 (6.92%) Close

$OCGN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense
Amortization (accretion) on marketable securities
Amortization of Debt Issuance Costs
Non-cash interest expense
In-process research and development
Change in fair value of derivative liability
Non-cash (income) expense from collaborative arrangements, net
Non-cash lease expense
Non-cash income from collaborative arrangements, net
Non-cash expense (income) from collaborative arrangements, net
Stock-based compensation expense
Loss on debt conversion
Income tax benefit
Gain on forgiveness of Paycheck Protection Program note
Impairment on note receivable
Impairment of advance for COVAXIN supply
Loss on disposal of fixed assets related to COVAXIN
Other
Changes in assets and liabilities:
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Lease obligations
Other assets

Net cash used in operating activities
Cash flows from investing activities
Purchases of marketable securities
Proceeds from the maturities of marketable securities
Purchases of property and equipment
Asset acquisition
Issuance of note receivable
Repayment of note receivable
Payment of security deposits
Net cash (used in) provided by investing activities

Cash flows from financing activities
Proceeds from issuance of common stock
Payment of equity issuance costs
Purchases of treasury stock
Proceeds from Pre-Merger Financing
Proceeds from issuance of debt
Payments of debt issuance costs
Repayments of debt
Financing lease principal payments
Payment of EB-5 loan
Net cash provided by financing activities

Effect of changes in exchange rate on cash and restricted cash
Net (decrease) increase in cash and restricted cash
Cash and restricted cash at beginning of period
Cash and restricted cash at end of period
Supplemental disclosure of non-cash investing and financing transactions:
Series B Convertible Preferred Stock issuance
Exercise of warrants
Forgiveness of Paycheck Protection Program note
Purchase of property and equipment
Issuance of Warrant Exchange Promissory Notes
Debt issuance costs
Right-of-use assets related to operating leases
Series B Convertible Preferred Stock reacquisition
Issuance of common stock for Avenue Capital agreement
Conversion of convertible notes
Reverse asset acquisition costs

Comments